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Strengths and limitations of this study
 ► The Surveillance After Extremity Tumor Surgery 
(SAFETY) trial will be an international multi-centre 
2×2 factorial randomised controlled trial.
 ► The trial will answer a high priority question for sar-
coma surgeons.
 ► The SAFETY trial will build on the international 
collaboration and experience of the Prophylactic 
Antibiotic Regimens in Tumor Surgery (PARITY) trial.
 ► The feasibility pilot study is essential before under-
taking this large multi-centre trial.
 ► The success of the pilot study is dependent on the 
ability of clinical sites to recruit patients, comply 
with the protocol and complete high-quality fol-
low-up data.
AbStrACt
Introduction Following the treatment of patients with 
soft tissue sarcomas (STS) that are not metastatic at 
presentation, the high risk for local and systemic disease 
recurrence necessitates post-treatment surveillance. 
Systemic recurrence is most often detected in the lungs. 
The most appropriate surveillance frequency and modality 
remain unknown and, as such, clinical practice is highly 
varied. We plan to assess the feasibility of conducting 
a multi-centre randomised controlled trial (RCT) that 
will evaluate the effect on overall 5-year survival of two 
different surveillance frequencies and imaging modalities 
in patients with STS who undergo surgical excision with 
curative intent.
Methods and analysis The Surveillance After Extremity 
Tumor Surgery trial will be a multi-centre 2×2 factorial 
RCT. Patients with non-metastatic primary Grade II or III 
STS treated with excision will be allocated to one of four 
treatment arms1: chest radiograph (CXR) every 3 months 
for 2 years2; CXR every 6 months for 2 years3; chest CT 
every 3 months for 2 years or4 chest CT every 6 months 
for 2 years. The primary outcome of the pilot study is the 
feasibility of a definitive RCT based on a combination of 
feasibility endpoints. Secondary outcomes for the pilot 
study include the primary outcome of the definitive trial 
(overall survival), patient-reported outcomes on anxiety, 
satisfaction and quality of life, local recurrence-free 
survival, metastasis-free survival, treatment-related 
complications and net healthcare costs related to 
surveillance.
Ethics and dissemination This trial received provisional 
ethics approval from the McMaster/Hamilton Health 
Sciences Research Ethics Board on 7 August 2019 (Project 
number 7562). Final ethics approval will be obtained prior 
to commencing patient recruitment. Once feasibility has 
been established and the definitive protocol is finalised, 
the study will transition to the definitive study.
trial registration NCT03944798; Pre-results.
bACkground
Magnitude of the problem
Sarcomas are malignancies of connective 
tissue that most commonly occur in the 
extremities. Sarcomas can arise within bone 
(bone sarcoma) or soft tissue (soft tissue 
sarcoma (STS)). Chemotherapy is not cura-
tive for the vast majority of patients with STS1; 
therefore, surgery is the standard treatment 
for STS, with radiation considered important 
for local disease control.
Following treatment for a STS that is not 
metastatic at presentation, the risk for local 
and systemic disease recurrence necessitates 
careful postoperative surveillance. Between 
40% and 50% of all patients with sarcoma 
will develop a local or distant recurrence; 
however, the risk of recurrence is greatest 
in the first few years, with 68% occurring by 
2 years and 90% by 5 years.2–4 Metastasis to the 
lung is the most frequent single location of 
disease recurrence in patients with sarcoma, 
occurring in the majority of patients with 
metastases.4–7 Therefore, routine follow-up 
after completing sarcoma treatment is stan-
dard practice in the first 5 years after surgery. 
These visits typically include a clinical 
history, physical examination and imaging 
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of the lungs (chest radiograph (CXR) or CT scan of the 
lungs).
Surveillance strategies for long-term follow-up of 
patients with sarcoma have not been well researched and 
current guidelines are based on expert opinion, not on 
high-quality evidence.8 9 As such, current clinical prac-
tice is highly varied, with survey data of musculoskeletal 
oncologists showing that the number of clinic visits ranges 
from 2 to 12, the number of CXRs obtained ranges from 
0 to 13, and the number of CT scans ranges from 1 to 8 
in the first year of surveillance.10–12 The current National 
Comprehensive Cancer Network (NCCN) guidelines 
suggest that stage II or III tumours should be followed 
with chest imaging (CT or CXR) every 2–6 months for the 
first 2–3 years and then annually thereafter, while stage I 
tumours could be followed less frequently during the first 
2–3 years.13
best evidence for surveillance strategies
Post-treatment STS surveillance is an integral element 
of patient care. Although earlier detection of metastatic 
disease may improve long-term survival, no study has yet 
provided definitive evidence to support this assumption. 
In order to assess the available evidence, we completed a 
systematic review of the available randomised controlled 
trial (RCT) evidence for surveillance in sarcoma 
management.14 A single study (published separately 
with early and longer-term follow-up) was identified.15 16 
The authors of this single-centre study found that 3-year 
overall and disease-free survival was not worse in patients 
with sarcoma who had less intensive surveillance (CXRs) 
than those with more intensive surveillance (CT scans).15 
Due to the sample size, this trial could not conclu-
sively demonstrate non-inferiority in overall or disease-
free survival for a 6-month interval of follow-up visits 
against 3-month interval (both were 64% and 69%, 
respectively).15
A follow-up study on the same patient cohort with 
5-year survival outcomes confirmed that more frequent 
follow-up did not improve survival and that, although CT 
scans detected pulmonary metastasis earlier, they did not 
lead to better survival compared with CXRs.16 However, 
this was a single-centre study with relatively small numbers 
and, therefore, confidence in the results and generalis-
ability of the data to other centres is limited. In addition, 
a relatively small proportion of screened patients (42%) 
that were eligible for the trial were included due to the 
exclusion of patients unlikely to follow-up, thus possibly 
introducing selection bias.15 Furthermore, low-grade 
sarcomas were eligible and included in this study, even 
though they have little metastatic potential and tumour-re-
lated mortality; their inclusion may have diminished the 
magnitude of the effects of the interventions.15 Finally, 
the majority of the included patients were patients with 
bone sarcoma, thereby limiting the interpretation to 
patients with STS.15
risks and benefits of intensive surveillance
Regular, intensive surveillance is more likely to iden-
tify recurrent disease earlier than would less intensive 
surveillance. This type of surveillance may provide reas-
surance to patients and clinicians; however, the adverse 
effects of intensive surveillance practices are also note-
worthy. The costs that healthcare systems incur as a result 
of sarcoma surveillance are substantial and could be in 
excess of US$20 000 for high-grade sarcomas.17 Further-
more, intensive surveillance can threaten the financial 
security of patients, due in part to the direct (including 
travel, accommodation, personal care and homemaking) 
and indirect costs (including lost wages for patients and 
their caregivers) incurred as a result of follow-up appoint-
ments.18 As a result, patients’ health and quality of life can 
be dramatically impacted.18–20
Secondary investigations and earlier knowledge of 
disease recurrence can also induce anxiety and impact 
the psychosocial well-being for those whose mortality risk 
cannot be significantly reduced by further medical inter-
ventions.21 Overcrowded clinics and long wait times may 
constitute other important factors that affect patients’ 
psychosocial well-being.22 Finally, the use of CT has raised 
concerns over unnecessary radiation exposure compared 
with radiographs, although lower-dose CT scans may miti-
gate some of these concerns.23
Surveillance research as a priority in orthopaedic oncology
We recently published a modified Delphi study in which 
we aimed to identify a clinically relevant consensus-based 
research agenda in the sarcoma field.24 From this Delphi 
process that included 80 orthopaedic oncologists and 
patient representation (with participation from 18 coun-
tries), we identified critical research priorities in the 
field of orthopaedic oncology and determined the top 
four feasible and important research questions that will 
directly inform patient care and enhance clinical prac-
tice. This study identified the evaluation of postoperative 
surveillance strategies as the highest-ranking research 
priority in the sarcoma field.24
PAtIEnt And PublIC InvolvEMEnt
To ensure that we maintain a patient-centred approach 
to the design and development of this study, we required 
the opportunity for open dialogue between the multidis-
ciplinary and international Surveillance After Extremity 
Tumor Surgery (SAFETY) study team, along with 
patient/caregiver representatives and other key stake-
holders. To facilitate their interaction and collaboration, 
we held an in-person Protocol Development Meeting in 
Toronto, ON, Canada in May 2018. At this meeting, we 
made critical decisions with respect to the study protocol, 
including (A) study design; (B) primary and secondary 
outcomes; (C) patient eligibility; (D) follow-up time 
frame; (E) methods to protect against bias; (F) randomi-
sation stratification and (G) further patient engagement. 
We also had the opportunity to discuss several issues that 
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Figure 1 Study of flow diagram.
may compromise the study’s success and strategise ways to 
manage these challenges, such as (i) acceptable surveil-
lance schedules that account for differences in interna-
tional standards of clinical practice; (ii) possible ethical 
concerns; (iii) patient compliance; (iv) local implementa-
tion and procedural variation; (v) competing studies and 
(vi) funding opportunities.
We are also conducting a patient survey to assess inter-
national patient willingness to participate in a study 
that randomises patients to a postoperative surveillance 
regimen in the management of a primary extremity 
sarcoma. Since there is no available validated tool to 
assess patient opinions and preferences, we developed 
a unique patient questionnaire for the purposes of this 
study. All new patients who present to a participating 
sarcoma clinic are screened for study participation. 
The preliminary survey questionnaire responses suggest 
that most patients with sarcoma believe that they have a 
good understanding of clinical research. Furthermore, 
over half of respondents feel comfortable with being 
randomised to receive a treatment. Ultimately, almost 
80% of respondents have indicated that they would agree 
to participate in the SAFETY trial if eligible.
Study dESIgn
We plan to assess the feasibility of conducting the prag-
matic, international, multi-centre, 2×2 factorial SAFETY 
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RCT that answers the following questions: In extremity, 
patients with STS who undergo surgical resection with 
curative intent,1 what is the impact of surveillance 
frequency (every 3 vs every 6 months) on overall survival 
at 5 years, and2 what is the impact of surveillance imaging 
modality (CXR vs CT scan) on overall survival at 5 years? 
To assess feasibility, we will conduct a pilot study. Study 
participants will be randomised to one of four possible 
treatment arms (see Study Interventions later). Randomi-
sation will occur at the end of active treatment (surgery 
±systemic treatment ±local radiation). Following the 
2-year intervention phase, study participants will continue 
to be assessed at regular intervals for an additional 3 years. 
As such, all pilot study patients will be transitioned into 
the definitive study and be included in it. Details of the 
flow of each study arm are outlined in figure 1. We antic-
ipate the duration of the pilot study to be 3 years in order 
to collect intervention phase data on all participants. 
The primary outcome of the pilot study is the feasibility 
of a definitive RCT based on a combination of feasibility 
endpoints.
The 2×2 factorial study design is ideal and the most 
efficient method to study two treatment interventions 
in a single RCT, particularly when there is no interac-
tion between the two interventions. This is unlike a 
scenario in which the two interventions are medica-
tions that may have a synergistic or negative effect when 
combined. A Bayesian design would be useful do avoid 
the question of whether or not an interaction exists, 
however for the purposes of the present trial it is clear 
that no interaction exists between the frequency and 
intensity of surveillance. As Freidlin and Korn discuss 
in their commentary, the 2×2 factorial design is an effi-
cient design to evaluate two interventions in a cancer 
clinical trial when there are no interactions between 
treatments.25
objECtIvES
Pilot study primary research objectives
The primary objective of the pilot study will be to deter-
mine whether it is feasible to conduct a large multi-centre 
RCT that will evaluate the impact of surveillance strate-
gies on patient survival following extremity STS surgery. 
To do so, we will assess our ability to:
1. Recruit patients across multiple participating clinical 
sites;
2. Ensure compliance with the study protocol, including 
the application of eligibility criteria, timing of inter-
vention phase and post-intervention phase visits and 
imaging modality;
3. Maintain completeness of follow-up data;
4. Maintain completeness of cost analysis data and
5. Maintain data quality.
Pilot study secondary research objectives
The secondary objectives of the pilot study will include 
assessing the impact of either surveillance frequency 
(every 3 vs every 6 months) or imaging modality (CXR vs 
CT scan) on:
1. Overall survival;
2. Patient anxiety, satisfaction and quality of life;
3. Local recurrence-free survival (LRFS) and metasta-
sis-free survival (MFS);
4. Treatment-related complications and
5. Net direct healthcare costs and net costs of treatment 
and treatment-related complications once metastases 
are detected.
HyPotHESIS
Pilot study
We hypothesise that the SAFETY trial will be feasible 
due to (A) its pragmatic design; (B) our established 
international collaborative research network; (C) our 
qualified, multidisciplinary study team; (D) our existing 
trial infrastructure and (E) the priority of the study 
question.
definitive study
There are two hypotheses:
1. More frequent postoperative surveillance (compared 
with less frequent postoperative surveillance) in the 
first 2 years following the surgical excision of a STS will 
improve survival over 5 years;
2. The use of postoperative CT scans (compared with 
CXR) in the first 2 years following the surgical excision 
of a STS will improve survival over 5 years.
Study SEttIng
This study will be coordinated by the Methods Centre 
within the Centre for Evidence-Based Orthopaedics at 
McMaster University (Hamilton, ON, Canada). For the 
pilot study, we expect that patients will be enrolled from 
10 clinical sites across four continents. Clinical sites 
will be carefully screened prior to participation in the 
study. The clinical site inclusion criteria are as follows: 
(i) adequate research personnel and infrastructure to 
manage the study; (ii) sufficiently high extremity STS 
volume to complete enrolment within the study time-
line (defined as greater than or equal to (≥) 20 patients 
per year); (iii) commitment from all or most ortho-
paedic oncologists to participate in the trial and (iv) 
access to the two imaging modalities. The exclusion 
criteria are as follows: (i) a lack of interest in the trial; 
(ii) anticipated challenges with protocol compliance; 
(iii) conflicting studies, in the judgement of the Prin-
cipal Investigator, that would inhibit patient participa-
tion and (iv) financial or contract constraints.
PAtIEnt ElIgIbIlIty CrItErIA
Inclusion criteria
Patients who meet all of the following criteria will be 
included:
1. Age of 18 years or older;
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2. Diagnosed with a primary extremity grade II or III STS;
3. Undergone surgical resection of the tumour with cu-
rative intent and grossly negative margins (R0 or R1 
resection margins);
4. Completed neoadjuvant or adjuvant radiation and/or 
chemotherapy, if applicable;
5. The tumour size is greater than or equal to (≥) 5 cm 
according to the pathology report or pre-treatment 
MRI if neoadjuvant radiation and/or chemotherapy 
are given; and
6. Provision of informed consent.
Exclusion criteria
Patients who meet any of the following criteria will be 
excluded:
1. Metastatic disease at initial presentation based on 
thoracic imaging (a second CT scan may be required 
to confirm that indeterminate nodules are false posi-
tives before the patient can be enrolled provided that 
the second CT scan shows no evidence of metastatic 
disease);
2. Undergone surgical excision of a local recurrence;
3. Diagnosis of one of the special subtypes: myxoid/
round cell liposarcoma or extra-skeletal Ewing’s 
sarcoma (these sarcomas have different metastat-
ic patterns, which necessitate different surveillance 
protocols);
4. Previous diagnosis of a genetic syndrome with an 
elevated risk of malignancy, such as Li-Fraumeni 
Syndrome (such individuals appear to be at an ele-
vated risk for radiation-induced cancers, so the use of 
CT scans should be limited);
5. Previous diagnosis with a comorbid condition that 
has a life expectancy of less than 1 year;
6. The site-specific surveillance protocol for the pa-
tient’s disease is not compatible with the study pro-
tocol (ie, regular planned whole-body imaging with 
positron emission tomography scans);
7. Diagnosed with another malignancy within the past 
5 years;
8. Likely problems, in the judgement of the investigator, 
with maintaining follow-up;
9. Currently enrolled in a study that does not permit 
co-enrollment;
10. The patient has already been enrolled in the SAFETY 
trial.
rECruItMEnt And SCrEEnIng
Each participating clinical site will have a locally respon-
sible investigator who will oversee the local administra-
tion of the trial, screen patients with STS for eligibility 
and develop a site-specific patient enrolment plan. A 
screening form will be completed for all patients with 
STS aged 18 years or older, irrespective of whether they 
are eligible to participate in the study or not. Patients will 
become eligible, will be screened and consented during 
the first clinic visit at which all treatment is complete, the 
surgical wound has healed, and the plan for post-treat-
ment surveillance is discussed with the patient. The 
process of obtaining and documenting informed consent 
will be completed in accordance with local Good Clin-
ical Practice recommendations. Consent procedures 
will comply with the appropriate ethics committee and 
the Health Insurance Portability and Accountability Act 
(where applicable).
rAndoMISAtIon And AlloCAtIon of PAtIEntS to Study 
grouPS
A centralised and automated internet-based randomisa-
tion system using random variable block sizes will assign 
participants to the study groups. Study personnel at 
each participating site will complete this task. Randomi-
sation will occur only after eligibility is confirmed and 
consent to participate has been obtained. Participants 
will be stratified based on clinical site and perioperative 
chemotherapy.
Study IntErvEntIonS
Participants will be randomised to one of four treatment 
groups:
1. CXR every 3 months for 2 years;
2. CXR every 6 months for 2 years;
3. Chest CT every 3 months for 2 years or
4. Chest CT every 6 months for 2 years.
Following completion of the intervention phase, partic-
ipants will continue to be followed in the study for an 
additional 3 years. During this 3-year post-intervention 
phase, participants will be followed at least every 6 months 
as per NCCN guidelines.13 If possible, thoracic imaging 
will continue at each scheduled post-intervention phase 
visit according to the participants’ original allocations.
rElAPSE
Local imaging and clinical assessment of the primary 
tumour site will be carried out as per the standard protocol 
at each participating clinical site. Further diagnostic tests 
will be performed in the presence of clinical symptoms or 
radiologic findings suggestive of disease relapse. Recur-
rence will be radiologically or histologically confirmed 
and classified as local or systemic (metastasis) recurrence. 
The first modality suggesting disease relapse in partici-
pants with confirmed local or systemic recurrence will be 
recorded as responsible for its detection.
outCoME MEASurES
Pilot study primary outcome
To evaluate feasibility, we will assess the number of 
patients screened and recruited at each participating clin-
ical site, participant retention and maintenance of data 
quality. In addition, we will evaluate the utilisation of an 
internet-based centralised randomisation system focusing 
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on the accuracy of data entry, appropriate stratification 
of participants and the minimisation of randomisation 
errors. Finally, we will evaluate investigator and partici-
pant compliance with the study protocol, including the 
application of eligibility criteria, compliance with the 
surveillance imaging and frequency regimens, frequency 
of crossover and timing of post-intervention phase visits. 
As discussed by Moore et al, the pilot study will investigate 
the process of the proposed definitive trial rather than 
its outcomes.26 The a priori criteria for the success of the 
pilot study are listed below:
1. Recruitment measure: We will consider our recruitment 
strategy feasible if we are able to enrol the pilot sample 
of 195 patients (approximately 20 patients from each 
clinical site participating in the pilot study) within 
2 years. See sample size determination later. As such, 
we will aim to recruit 100 patients during the first year. 
If we are unable to achieve at least 90% of this goal (90 
patients), then we will plan to increase the number of 
participating sites as a study rescue measure.
2. Protocol adherence measure: During the pilot study of the 
PARITY trial, we were able to maintain an overall pro-
tocol adherence rate in excess of 90%.27 Recent reports 
prepared for the PARITY Data and Safety Monitoring 
Board (DSMB) indicate a similar protocol adherence 
rate. However, given the greater complexity and lon-
ger duration of the SAFETY trial interventions, we will 
consider our protocol adherence strategies feasible if 
there is adherence of 85% or greater to the visit win-
dows and imaging modality prescribed by the protocol.
3. Participant retention measure: While 20% loss-to-follow-up 
has traditionally been considered acceptable in clinical 
research, evidence from other orthopaedic trials suggests 
that bias begins to affect study results at even lower rates 
of loss-to-follow-up.28 Therefore, we will consider our par-
ticipant retention strategies feasible if no more than 15% 
of participants are lost-to-follow-up.
4. Maintenance of data quality measure: We obtained a data 
completeness rate of approximately 90% in the PARITY 
trial pilot study.27 Therefore, we will consider our data 
quality strategies feasible if we are able to maintain 
95% or greater completeness of participant follow-up 
data for the definitive primary outcome. We will also 
consider our data quality strategies feasible if we are 
able to maintain 85% or greater completeness of par-
ticipant follow-up data for the secondary outcomes.
Pilot study secondary outcomes
Death from any cause will be recorded during the pilot 
study. Data on secondary outcomes for the definitive 
trial, which are listed below, will also be collected. These 
include:
1. Patient-reported outcome measures: The validated Patient-
Reported Outcomes Measurement Information System 
(PROMIS) Cancer-Anxiety questionnaire, PROMIS 
Satisfaction with Social Roles and Activities questionnaire 
and the EuroQol-5 Dimension will be used to assess pa-
tient anxiety, satisfaction and quality of life, respectively. 
These questionnaires will be administered at the base-
line visit, as well as the 6-month, 12-month, 18-month 
and 24-month intervention phase, as well as 36-month, 
48-month and 60-month post-intervention phase visits.
2. LRFS outcome measure: LRFS will be defined as the 
length of time from randomisation that the participant 
survives with no detection of recurrent disease at the 
initial tumour site or operative field.
3. MFS outcome measure: MFS will be defined as the length 
of time from randomisation that the participant sur-
vives with no detection of systemic disease recurrence 
at any anatomic location.
4. Treatment-related complications outcome measures: Treat-
ment-related complications will include both chemo-
therapy-related complications, such as febrile neutro-
paenia, fungal infections or sepsis and thoracotomy-re-
lated complications, such as pneumothorax or surgical 
site infections.
5. Net healthcare costs outcome measures: We will perform an 
incremental cost analysis of net costs of surveillance 
and costs incurred from metastasis treatment and me-
tastasis treatment-related complications. Unit costs for 
all resources used by trial participants will be obtained 
from regional statistics and from centres participating 
in the trial. These unit costs will be combined with the 
resource volumes to obtain a net cost per participant 
over their time in the trial.
ProtECtIng AgAInSt SourCES of bIAS
Adjudication of outcomes
An independent Central Adjudication Committee (CAC) 
will review all situations where eligibility is in doubt, as 
well as all reported instances of disease relapse, treat-
ment-related complications and death to determine 
whether a study event has occurred. The SAFETY CAC 
will be comprised of two orthopaedic oncologists, one 
medical oncologist and one radiologist. All participating 
clinical sites will submit digital imaging and relevant 
hospital records to the Methods Centre via a web-based 
platform for events that require adjudication.
blinding
The local clinical team, site study personnel and partici-
pants cannot be blinded to the treatment allocation. The 
CAC will be blinded to surveillance frequency. The data 
analysts will, however, remain blinded during the trial’s 
analysis.
Maximisation of follow-up
We anticipate only minimal losses to follow-up in our 
musculoskeletal oncology population. Nonetheless, the 
following procedures will be implemented to minimise 
losses:
▪ Individuals likely to present problems with compli-
ance to the study protocol or maintaining follow-up will 
be excluded;
▪ At the time of randomisation, participants will be 
asked to provide their contact information, as well as the 
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Table 1 Sample size per group for 80% power, α=0.05
Event rate in more intensive 
surveillance group
25% 30% 35% 40%
Event rate in less 
intensive surveillance 
group
35% 696 2832 – –
40% 332 752 3020 –
45% 196 352 792 3148
50% 132 204 368 816
55% 96 136 212 372
Event rate=death
contact information of their family physician and three 
alternate contacts;
▪ Participants who refuse to return for a study assess-
ment will be asked if they are willing to provide follow-up 
data (to determine survival and to complete study ques-
tionnaires) via telephone;
▪ If a participant cannot be reached, their status 
regarding the primary study outcome will be assessed by 
reviewing their medical records;
▪ Study personnel will remind participants of upcoming 
clinic visits;
▪ To assuage possible concerns related to less frequent 
follow-up, participants will be encouraged to schedule an 
ad hoc visit anytime they are concerned, even if it breaks 
the surveillance protocol to which they were assigned;
▪ Participants will be provided with access to educa-
tional content, such as a video that demonstrates how to 
self-examine for a local recurrence of their STS and
▪ Parking and travel vouchers will be provided to partic-
ipants, where possible, to alleviate the costs associated 
with the study.
Minimisation of crossovers of surveillance interventions
Crossovers are unlikely for either surveillance inter-
vention as investigators will be requesting the imaging 
modality during surveillance visits. Any deviation with 
regards to frequency or imaging modality will be docu-
mented. In the event of disease recurrence or progres-
sion, the following standardised management protocols 
will be adopted:
▪ Local recurrence: the participant will have a lung CT 
scan to confirm no progression of their systemic disease 
before continuing with the study protocol.
▪ Metastases: the participant will no longer be followed 
as per the study protocol, but per the appropriate 
follow-up for the interventions required for the treatment 
of metastases; however, the participant will continue to be 
followed in the trial.
For both events, the specific imaging modality used to 
detect either the local recurrence or the metastases will 
be documented.
Patients that have incidental or off-protocol imaging 
will not crossover; however, this will be documented as 
a protocol deviation. In the case of a CXR that warrants 
further investigation with a CT scan, this will be docu-
mented. If the patient is found to have disease recur-
rence, we will document how the disease recurrence was 
(A) first identified and (B) confirmed. If after a CT scan 
the patient is found to not have disease recurrence, the 
patient will resume surveillance as per the arm to which 
they were randomised.
SAMPlE SIzE dEtErMInAtIon
Pilot study sample size
The CI approach was used to calculate the required 
sample size for the pilot study.29 We determined a priori 
that the definitive trial would only be feasible if our 
protocol adherence rate was at least 85%. Using a 95% 
CI and a 5% margin of error, we calculated a required 
sample size of 195 patients.
definitive study sample size
Our best estimate of the control group overall 5-year 
survival for both the surveillance frequency and imaging 
modality is 55%.16 Given that intensive surveillance will 
detect metastatic disease at an earlier stage, we will use 
a superiority design to compare survival between more 
versus less intensive surveillance. A 10% absolute increase 
in overall 5-year survival associated with both more 
frequent surveillance and the use of CT scans represents 
a clinically important difference, as outlined by the Amer-
ican Society of Clinical Oncology’s statement on clini-
cally meaningful outcomes in cancer trials.30 Therefore, 
the definitive trial will be powered to detect an absolute 
difference of 10% in overall 5-year survival.
With a desired power of 0.80, we calculated a sample 
size of 396 participants per study arm. We will account 
for a 5% loss to follow-up and, therefore, the final sample 
size will be 830 participants. Table 1 shows various sample 
sizes for pairwise comparisons of alternative surveillance 
frequencies/imaging modalities given varying control 
event rates and absolute increases in survival. Statistical 
Package for the Social Sciences (IBM Corporation) soft-
ware was used for sample size calculation.
The definitive sample size calculation may be adjusted 
as we prepare for the transition from the pilot to the 
definitive study as a result of data collected during the 
pilot study. One factor we may consider will be the 
percent lost to follow-up by the end of the pilot study. 
Other factors such as the estimated control group overall 
5-year survival, the clinically meaningful outcome and 
power cannot be amended. The rationale for transition 
of subject data from the pilot study to the definitive study 
has previously been discussed.31 It is acceptable to pool 
the data if the study methods are not adjusted following 
the pilot study, and the research tools are standardised.
AnAlySIS of fEASIbIlIty outCoMES
A full description of the measures, variables and 
methods of analysis are shown in table 2. We will record 
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Table 2 Summary of feasibility outcomes analysis plan
Objective Outcome
Criteria for success of 
feasibility Method of analysis
To determine the feasibility of 
conducting the multi-centre 
SAFETY international RCT
Recruitment measure Enrolment of pilot sample 
within 2 years
Descriptive statistics—
reported as counts (percent) 
for categorical variables and 
means (SD) for continuous 
variables with 95% CI
Protocol adherence measure Protocol adherence of 85% or 
greater
Participant retention measure Loss-to-participant follow-up 
of 15% or less
Maintenance of data quality 
measure
Data completeness of 95% 
or greater for the definitive 
primary outcome
Data completeness of 85% 
or greater for the secondary 
outcomes
RCT, randomised controlled trial; SAFETY, Surveillance After Extremity Tumor Surgery.
the total number of participants enrolled on a monthly 
basis. Each participating site will keep a Screening Log 
of included and excluded patients. We will also keep 
a record of participants who miss visits, and those 
who are withdrawn or lost to follow-up. These will be 
reported using descriptive statistics—reported as counts 
(percent) for categorical variables and mean (SD) for 
continuous variables with 95% CIs. We will report the 
proportion of complete Case Report Form (CRFs) as 
descriptive data.
AnAlySIS of dEfInItIvE Study PrIMAry outCoME
The analysis and reporting of the trial will follow the 
Consolidated Standards of Reporting Trials criteria.32 
The primary analysis will compare the treatment groups 
on the overall 5-year survival. Two independent compar-
isons between treatment groups will be made using Cox 
regression models with time to the definitive primary 
endpoint.33 Results will be expressed as effect (ORs for 
binary outcomes, HRs for time-dependent outcomes 
and mean difference for continuous outcomes), corre-
sponding two-sided 95% CIs and associated p-values.
EtHICAl ConSIdErAtIonS
This study is to be conducted according to international 
standards of Good Clinical Practice, applicable govern-
ment regulations and institutional research policies and 
procedures. All study intervention phase (surveillance) 
arms fall within the spectrum of current standard prac-
tice, as do the standardised post-intervention phase 
follow-up visits. The study protocol will be submitted to 
a properly constituted independent ethics committee, 
in agreement with local legal prescriptions, for formal 
approval of the study conduct at each participating clin-
ical site. A copy of this approval will be provided to the 
Methods Centre by each participating clinical site prior 
to the local commencement of the study.
Study tIMElInE
We expect that the pilot study will take just over 3 years to 
complete. We estimate that recruitment will take approx-
imately 1 year to complete per site. The initiation of 
screening and enrolment will likely be staggered across 
the participating clinical sites due to the variability in the 
time required to obtain ethics approval and negotiate 
institutional contracts. Therefore, the pilot study recruit-
ment timeline will be up to 2 years. We expect a further 
1 year for all pilot participants to complete the interven-
tion phase of the trial. Although we will not have complete 
post-intervention phase data for any pilot participants, we 
anticipate being able to determine feasibility at the end of 
the intervention phase based on our feasibility objectives. 
We plan a priori to transition directly from the pilot to the 
definitive study if feasibility is established.
dAtA SAfEty MonItorIng boArd
As per the principles established by the Data Moni-
toring Committees: Lessons, Ethics, Statistics Study 
Group charter, a DSMB will oversee the safety of the trial 
participants and the overall conduct of the trial. The 
Committee members will be independent of the trial, 
free of conflicts with any of the investigative team, and 
will consist of two orthopaedic oncologists, a medical 
oncologist, a radiologist and a biostatistician. The DSMB 
will frequently review enrolment and demographic 
summaries, listings of protocol deviations, and summa-
ries and listings of serious adverse events. They will advise 
the Principal Investigator and SAFETY study team on any 
concerns related to participant safety and trial conduct 
and will make recommendations for (A) study contin-
uation as designed; (B) study termination; (C) study 
continuation with major or minor modifications or (D) 
temporary study suspension of enrolment until some 
uncertainty is resolved.
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knowlEdgE dISSEMInAtIon
The results of the study will be submitted for publication 
regardless of whether there are significant findings, as 
well as posted on  ClinicalTrials. gov. The trial has been 
registered on  clinicaltrials. gov. In addition to scientific 
manuscripts and presentations, we plan to prepare study 
reports and press releases for patients and other stake-
holders that are transparent, and that the language is 
understandable to the general public.
PotEntIAl IMPACt of tHE Study
The benefit of this pilot study would be to determine the 
feasibility of the SAFETY trial. This is essential prior to 
undertaking a large multi-centre RCT. Experience gained 
during the pilot study will provide insight into methods 
to increase enrolment, strategies to maintain protocol 
adherence and the adjustment of recruitment expecta-
tions. In addition, the ultimate success of the pilot study 
will support funding requests for the definitive study of 
the multi-centre SAFETY trial.
Once the feasibility endpoints are reached, we will tran-
sition directly into and begin recruiting for the definitive 
SAFETY trial. The ultimate goal of the SAFETY trial is to 
provide high-quality evidence for surveillance strategies 
following the treatment of STS, which will allow for the 
development of evidence-based clinical practice guide-
lines for patients with sarcoma worldwide.
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